196 results about "Cellular senescence" patented technology

The present invention relates to sirtuin 6 activating peptides, derived from highly conserved regions of human SIRT proteins, and to a cosmetic or pharmaceutical composition comprising at least one sirtuin 6 activating peptide in a physiologically acceptable medium. The invention further relates to the utilization of a cosmetic composition to prevent and/or repair DNA degradation, improve telomere maintenance and reduce cellular senescence. The invention also applies to a cosmetic treatment process intended to prevent and/or treat the cutaneous signs of aging and photo aging.

Compounds, and methods of using the same, are provided which increase the expression of telomerase reverse transcriptase (TERT) in a cell. These compounds and methods find use in a variety of applications in which increased expression of telomerase is desired, including immortalization of cell lines and treating conditions in a subject characterized by cellular senescence.

A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ECM) composition comprising ECM from an adolescent tissue source, the ECM comprising an exogenously added cytokine, and (ii) administering ECM composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule in the ECM composition and modulates ROS production of the cells, whereby, the cellular senescence is abated.

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.

Dysregulation of vascular function is observed in brain endothelium derived from patients affected by Alzheimer's disease. This may be manifested at the cell or organ level: e.g., abnormal capillary morphogenesis, defective angiogenesis, inappropriate cellular senescence, mitotic catastrophe, or combinations thereof. This observation can be used for diagnosis or treatment of neurodegenerative disorders and other cognitive impairments.

In accordance with one aspect of the present invention, methods have been developed for identifying compositions which support the culture of defined cell populations. In accordance with another aspect of the present invention, methods have been developed for identifying compositions which promote differentiation of defined cell populations. In accordance with yet another aspect of the present invention, methods have been developed for identifying compositions which induce apoptosis of defined cell populations. In accordance with still another aspect of the present invention, methods have been developed for identifying compositions which promote cell senescence of defined cell populations. In accordance with still another aspect of the present invention, methods have been developed for identifying media which modulate the retardation of cell growth of defined cell subpopulation(s). In accordance with further aspects of the present invention, there are provided novel compositions identified by invention methods. Also provided are various uses of the novel compositions identified by invention methods, and novel cell populations produced employing same. In accordance with still another aspect of the present invention, methods have been developed for identifying compositions which support the culture of aberrant cell populations. In accordance with yet another aspect of the present invention, methods have been developed for identifying compositions which promote differentiation of aberrant cell populations. In accordance with still another aspect of the present invention, methods have been developed for identifying compositions which induce apoptosis of aberrant cell populations.

The present invention belongs to the technical field of food, and discloses a Se-enriched natural nutritional food having a high nutritional value and a preparation method thereof. The Se-enriched natural nutritional food is prepared from the following raw materials: Se-enriched wild lobed kudzuvine root powder, Se-enriched amorphophalms konjac fine flour, common yam rhizome powder, oriental sesame seed, walnut meat and granulated sugar. The Se-enriched natural nutritional food has effects of improving metabolism of human tissues and organs, enhancing cardiovascular function, delaying cellular senescence, and has a better health care function. Furthermore, by the addition of selenium, the Se-enriched natural nutritional food can significantly prevent cancer and reduce the incidence of cancer. The Se-enriched natural nutritional food is a safe, effective, convenient and tasty table food for people.

Methods of preventing and reversing stem cell aging including the step of activating the mitochondrial unfolded protein response in a stem cell are described. Further described are methods of promoting stem cell maintenance and methods of preventing and/or reversing tissue degeneration or injury including the step of activating the mitochondrial unfolded protein response.

The invention relates to a human corneal endothelial cell culture solution as well as a preparation method and an application thereof. The solution comprises bovine corneal endothelial cell lysis solution with 10-200 mug/ml of protein as the main active component, fetal calf serum with the content being 10%, 100U/ml of penicillin, 100U/ml of streptomycin and the remainder being supplemented by D/F12 basal culture solution. The method comprises of: firstly culturing bovine corneal endothelial cell in vitro; preparing bovine corneal endothelial cell lysis solution and formulating in a disinfection chamber to obtain the product. The invention, for the first time, prepares bovine corneal endothelial cell lysis solution into cell culture solution and applies to in vitro culture of human corneal endothelial cells, can promote great augmentation of human corneal endothelial cells cultured in vitro, maintain form feature of corneal endothelial cells, inhibit cells from ageing and apoptosis, and facilitate the subculture of endothelial cells; wherein, the raw material bovine corneal endothelial cell has abundant source and is easy for in vitro culture, the preparation method of the culture solution is simple, easy to implement, conducive for industrialization, and has wide application and development prospect.

The invention discloses a sub-totipotent stem cell from cut human umbilical cord or placenta, wherein the cell marker is CD151<+>OCT4<+>CD184<->; the cell grows adhering to the wall in a culture container and can differentiate to the body entoderm, mesoblast and ectoderm tissues. The invention also discloses a preparation method of the sub-totipotent stem cell and an application thereof for preparing drug for treating cell injuries or cell aging diseases, and an application thereof as a carrier cell of a gene treatment drug.

Methods for increasing glucose induced insulin secretion in an insulin secreting cell by inducing senescence in the cell are provided. Further, methods for treating diabetes, by providing cells with increased glucose induced insulin secretion to a subject, as well as a population of modified insulin secreting cells are provided.

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.

The invention discloses an extraction and culture method of human umbilical cord mesenchymal stem cells. The umbilical cord tissue is cut up and digested by collagenase I and then transferred into a culture bottle containing a culture medium for continuous culture. The culture medium is a low-sugar DMEM (Dulbecco modified eagle medium) and is added with fetal bovine serum, fibroblast growth factor, epithelial cell growth factor, cell transcription factor and cholesterol. The extraction and culture method disclosed by the invention can culture human umbilical cord mesenchymal stem cells for a long time while maintaining the activity of the stem cells. Through the invention, the problems of excessively fast cell aging and differentiation in current culture of human umbilical cord mesenchymal stem cells are solved, and the human umbilical cord mesenchymal stem cells with the characteristics of stem cells can be obtained for a long time.

The invention discloses a fat-soluble biological composite fermentation accelerator, which belongs to the technical field of biological fermentation. The fermentation accelerator consists of a lipoid component, a vitamin component, an amino acid component, four growth factors and sesame oil. The fat-soluble biological composite fermentation accelerator can remarkably improve the permeability of cell membranes, supplement multiple nutrient components required for maintaining the growth of microbe, promote the division and propagation of microbial cells, obviously improve the content of living bacteria in fermentation liquor, protect the cells from being damaged by free radicals, and delay ageing and autolysis of the cells so as to prolong the time of synthesizing fermented metabolic products and fulfill the aim of increasing the yield of a target metabolic product.

The invention provides a skin whitening and freckle removing cosmetic containing a rhodiola rosea extract and an active polypeptide combination. The skin whitening and freckle removing cosmetic comprises the rhodiola rosea extract and the active polypeptide combination as well as a matrix auxiliary material, wherein the active polypeptide combination comprises water, glycerol, 1,2-pentanediol, caprylyl glycol, sodium pyroglutamate, nonapeptide-1 and carnosine. The skin whitening and freckle removing cosmetic provided by the invention has the advantages that the rhodiola rosea extract can delay cell aging and inhibit formation of lipofuscins and active oxygen in cells, nonapeptide-1 can stop tyrosinase from being further activated and no lipofuscin is formed, and carnosine can prevent free radicals produced due to smoking from appearing, so that the cosmetic provided by the invention has the effects of preventing senility of skin and whitening the skin; and active prevention and recuperation of traditional Chinese medicines are combined with passive prevention and treatment of western medicines, so that skin immunity is enhanced while prevention is carried out, irritability is low in a treatment process, and effect is obvious.

The invention discloses a health-care product for supplying brain nutrition, which is characterized by comprising the following components in parts by weight: 25-30 parts of pine nut oil, 15-20 parts of oryzanol, 15-20 parts of rice germ oil, 5-10 parts of linoleic acid, 5-10 parts of camellia seed oil, 5-10 parts of hickory oil, and 5-10 parts of a-linolenic acid. The health-care product for supplying brain nutrition disclosed by the invention is capable of nourishing cranial nerves, cells and myelin sheaths, repairing brain nerves and cells, delaying cell senescence, making brain healthy, being beneficial to intelligence, improving memory, promoting overall development of brain and relieving mental disorders and senile diseases, such as mental diseases, depression, hyperactivity, phobia, infantile autism and senile dementia and is applied to all people.

The present invention relates to a method for the generation of immortalized transduced cell lines susceptible to senescence whereby the senescence is exogenously inducible and said cells can switch severalfold between the senescent stage and the immortalized stage. In particular, the present invention relates to a method for the generation of immortalized transduced cell lines susceptible to senescence wherein two or more different immortalizing gene sequences have been incorporated whereby said immortalizing gene sequences are regulated by regulators controlled via exogenous means. In a further aspect, the present invention relates to immortalized transduced cell lines obtainable with said method. In addition, methods for screening molecules influencing senescence of cells are provided as well as kits for conducting the same.

The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging—and their neurological symptoms and manifestations, which includes administering d-methadone, beta-d-methadol, alpha-l-methadol, beta-l-methadol, alpha-d-methadol, acetylmethadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, beta-d-acetylmethadol, beta-l-acetylmethadol, d-alpha-normethadol, l-alpha normethadol, noracetylmethadol, dinoracetylmethadol, methadol, normethadol, dinormethadol, EDDP, EMDP, d-isomethadone, normethadone, N-methyl-methadone, N-methyl-d-methadone, N-methyl-l-methadone, l-moramide, levopropoxyphene, pharmaceutically acceptable salts, or mixtures thereof, including deuterated and tritium analogues, whether isolated from its enantiomer or synthesized de novo.